{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:16:45Z","timestamp":1776194205262,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.hfc.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T23:01:25Z","timestamp":1712962885000},"page":"333-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tafamidis in the Treatment of ATTR-related Cardiomyopathy"],"prefix":"10.1016","volume":"20","author":[{"given":"Teresa Maria","family":"Capovilla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lalario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hfc.2024.03.007_bib1","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.007_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.03.007_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1026440","article-title":"Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies","volume":"9","author":"Porcari","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"45","key":"10.1016\/j.hfc.2024.03.007_bib4","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.hfc.2024.03.007_bib5","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.007_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaccao.2021.05.004","article-title":"Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study","volume":"3","author":"Westin","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"36","key":"10.1016\/j.hfc.2024.03.007_bib7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hfc.2024.03.007_bib8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.hfc.2024.03.007_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2024.03.007_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","article-title":"Diagnosis of transthyretin amyloid cardiomyopathy","volume":"9","author":"Hafeez","year":"2020","journal-title":"Cardiol Ther"},{"issue":"8","key":"10.1016\/j.hfc.2024.03.007_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2024.03.007_bib12","first-page":"161","volume":"50","author":"Kelly","year":"1997"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.007_bib13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hfc.2024.03.007_bib14","unstructured":"European Medicines Agency, Vyndaqel 61 mg soft capsules. Summary of product characteristics, Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002294\/WC500117862.pdf. Accessed July 29, 2023."},{"key":"10.1016\/j.hfc.2024.03.007_bib15","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.hfc.2024.03.007_bib16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.hfc.2024.03.007_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2024.03.007_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hfc.2024.03.007_bib19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Supplement_2","key":"10.1016\/j.hfc.2024.03.007_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/ehaa946.2115","article-title":"Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy","volume":"41","author":"Rapezzi","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.007_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial","volume":"9","author":"Shah","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.007_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of Tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.007_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hfc.2024.03.007_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The bioequivalence of Tafamidis 61-mg free acid capsules and Tafamidis meglumine 4 \u00d7 20-mg capsules in healthy volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.hfc.2024.03.007_bib26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaccao.2021.08.007","article-title":"Effect of Tafamidis on serum transthyretin lev- els in non-trial patients with transthyretin amyloid cardiomyopathy","volume":"3","author":"Falk","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.hfc.2024.03.007_bib27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of Tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"EHJ - Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2024.03.007_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0735-1097(22)01297-9","article-title":"Tafamidis effectiveness in wild-type transthyretin cardiac amyloidosis by mayo staging","volume":"79","author":"Amaka","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2024.03.007_bib29","doi-asserted-by":"crossref","first-page":"A12093","DOI":"10.1161\/circ.144.suppl_1.12093","article-title":"Abstract 12093: Tafamidis use and new onset atrial fibrillation in patients with cardiac amyloidosis","volume":"144","author":"Sweat","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2024.03.007_bib30","first-page":"767","article-title":"Cardiac imaging in Tafamidis-treatment patients with transthyretin amyloid cardiomyopathy","volume":"42","author":"Rettl","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2024.03.007_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpcardiol.2022.101358","article-title":"Impact of Tafamidis on survival in a real-world community-based cohort","volume":"47","author":"Hussain","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.hfc.2024.03.007_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with Tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"Bezard","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.007_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2024.03.007_bib34","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"17","key":"10.1016\/j.hfc.2024.03.007_bib35","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2024.03.007_bib36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial Tafamidis, the most expensive cardiac medication in history","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hfc.2024.03.007_bib37","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.007_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.007_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2024.03.007_bib42","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC Basic to Transl Sci"},{"issue":"10","key":"10.1016\/j.hfc.2024.03.007_bib43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hfc.2024.03.007_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.007_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.007_bib46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:26:52Z","timestamp":1717590412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713624000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1551713624000254"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2024.03.007","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tafamidis in the Treatment of ATTR-related Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}